JFG
ABCL icon

Jefferies Financial Group’s AbCellera Biologics ABCL Stock Holding History

Jefferies Financial Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.58M Buy
+2,746,200
New +$9.88M 0.07% 211

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Financial Group's ABCL Position: Q1 2026 in Review

Jefferies Financial Group opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 2,746,200 shares worth $9.58M. The stake represents 0.07% of the portfolio and ranks #211 among its holdings.

138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Jefferies Financial Group held 2,746,200 shares of AbCellera Biologics worth $9.58M as of Q1 2026.
  • AbCellera Biologics was a new Jefferies Financial Group position in Q1 2026.
  • AbCellera Biologics made up 0.07% of Jefferies Financial Group's portfolio in Q1 2026, its #211 holding.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.